Skip to main content

Anti-HER2 Treatments Can Cause Pulmonary Toxicities in HER2+ Breast Cancer

Charles Powell, MD, System Chief for Pulmonary, Critical Care and Sleep Medicine at the Icahn School of Medicine

View the article and video from Targeted Oncology, in which Charles A. Powell, MD, discusses pulmonary toxicities when using anti-HER2 monoclonal antibodies such as trastuzumab deruxtecan (Enhertu) for patients with HER2-positive metastatic breast cancer.

Learn More